Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Faculty

Emma Ciafaloni, MD

Professor of Neurology and Pediatrics
University of Rochester
Rochester, New York

Disclosures

Emma Ciafaloni, MD, has the following relevant financial relationships:
Consultant or advisor for: Alexion Pharmaceuticals, Inc.; Amicus Therapeutics, Inc.; argenx; Biogen; Dyne; Janssen; Momenta Pharmaceuticals, Inc.; NS Pharma, Inc.; PTC Therapeutics; Sanofi; Sarepta Therapeutics, Inc.; Scholar Rock; Viela Bio, Inc.; Wave
Research funding from: Sarepta Therapeutics, Inc.

Diana P. Castro, MD

Neurologist With Special Qualification in Child Neurology
Pediatric Neuromuscular Neurologist
Medical Director, Neurology and Neuromuscular Care Center
President, Neurology Rare Disease Center
Dallas, Texas

Disclosures

Diana P. Castro, MD, has the following relevant financial relationships:
Consultant or advisor for: Biogen; Novartis; PTC Therapeutics; Sarepta Therapeutics, Inc.
Research funding from: Biogen; FibroGen, Inc.; ReveraGen; Sarepta Therapeutics, Inc.; Scholar Rock

Nancy Kuntz, MD

Professor of Pediatrics and Neurology
Northwestern University and Feinberg School of Medicine
Chicago, Illinois

Disclosures

Nancy Kuntz, MD, has the following relevant financial relationships:
Consultant or advisor for: argenx; Biogen; FibroGen, Inc.; Novartis; Sarepta Therapeutics, Inc.
Speaker or member of speakers bureau for: Sarepta Therapeutics, Inc.
Research funding from: argenx; Astellas Pharma, Inc.; FibroGen, Inc.; Novartis; Roche; Sarepta Therapeutics, Inc.

Editors

Pakinam Aboulsaoud, PharmD

Senior Medical Education Director, Medscape, LLC

Disclosures

Pakinam Aboulsaoud, PharmD, has no relevant financial relationships.

Yoji Yamaguchi, MA, ELS

Scientific Content Manager, Medscape, LLC

Disclosures

Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

CME

Highlights in the Care of Duchenne Muscular Dystrophy: A Microlearning Experience

Authors: Emma Ciafaloni, MD; Diana P. Castro, MD; Nancy Kuntz, MD
CME Released: 4/26/2023
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 4/26/2024, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for neurologists, pediatricians, primary care physicians, and other clinicians who manage patients with neuromuscular diseases.

The goal of this activity is for learners to be better able to utilize current and emerging approaches for the timely diagnosis and optimal treatment of patients with DMD.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Role of specific testing tools to arrive at a timely and accurate diagnosis of DMD
- Pathophysiologic basis of DMD
- Factors involved in the selection of patients with DMD for RNA-based exon skipping therapies
- Differences between gene therapies being studied for the management of DMD
- Current clinical data for gene therapies being studied for the management of DMD

Disclosures

Disclosures for additional planners can be found here.

Faculty

Emma Ciafaloni, MD

Professor of Neurology and Pediatrics
University of Rochester
Rochester, New York

Disclosures

Emma Ciafaloni, MD, has the following relevant financial relationships:
Consultant or advisor for: Alexion Pharmaceuticals, Inc.; Amicus Therapeutics, Inc.; argenx; Biogen; Dyne; Janssen; Momenta Pharmaceuticals, Inc.; NS Pharma, Inc.; PTC Therapeutics; Sanofi; Sarepta Therapeutics, Inc.; Scholar Rock; Viela Bio, Inc.; Wave
Research funding from: Sarepta Therapeutics, Inc.

Diana P. Castro, MD

Neurologist With Special Qualification in Child Neurology
Pediatric Neuromuscular Neurologist
Medical Director, Neurology and Neuromuscular Care Center
President, Neurology Rare Disease Center
Dallas, Texas

Disclosures

Diana P. Castro, MD, has the following relevant financial relationships:
Consultant or advisor for: Biogen; Novartis; PTC Therapeutics; Sarepta Therapeutics, Inc.
Research funding from: Biogen; FibroGen, Inc.; ReveraGen; Sarepta Therapeutics, Inc.; Scholar Rock

Nancy Kuntz, MD

Professor of Pediatrics and Neurology
Northwestern University and Feinberg School of Medicine
Chicago, Illinois

Disclosures

Nancy Kuntz, MD, has the following relevant financial relationships:
Consultant or advisor for: argenx; Biogen; FibroGen, Inc.; Novartis; Sarepta Therapeutics, Inc.
Speaker or member of speakers bureau for: Sarepta Therapeutics, Inc.
Research funding from: argenx; Astellas Pharma, Inc.; FibroGen, Inc.; Novartis; Roche; Sarepta Therapeutics, Inc.

Editors

Pakinam Aboulsaoud, PharmD

Senior Medical Education Director, Medscape, LLC

Disclosures

Pakinam Aboulsaoud, PharmD, has no relevant financial relationships.

Yoji Yamaguchi, MA, ELS

Scientific Content Manager, Medscape, LLC

Disclosures

Yoji Yamaguchi, MA, ELS, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Neurology & Neurosurgery

CME

Highlights in the Care of Duchenne Muscular Dystrophy: A Microlearning Experience

Authors: Emma Ciafaloni, MD; Diana P. Castro, MD; Nancy Kuntz, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 4/26/2023

Valid for credit through: 4/26/2024, 11:59 PM EST

processing....

Select Any Chapter to Begin

Page 1 of 25

When to Consider Duchenne Muscular Dystrophy and the Role of Creatine Kinase - Pre-Assessment

CME Information Download Slides

Activity Transcript

Print
Like Tweet

Activity Transcript

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Emma Ciafaloni, MD

Diana P. Castro, MD

Nancy Kuntz, MD

Editors

Pakinam Aboulsaoud, PharmD

Yoji Yamaguchi, MA, ELS

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

CME

Highlights in the Care of Duchenne Muscular Dystrophy: A Microlearning Experience

Target Audience and Goal Statement

Disclosures

Faculty

Emma Ciafaloni, MD

Diana P. Castro, MD

Nancy Kuntz, MD

Editors

Pakinam Aboulsaoud, PharmD

Yoji Yamaguchi, MA, ELS

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Highlights in the Care of Duchenne Muscular Dystrophy: A Microlearning Experience

Select Any Chapter to Begin